A study to determine the efficacy of Siddha prebiotic drug Panchadeepakini chooranam in Psoriasis

A comparative open label study to evaluate the effficacy of Siddha prebiotic Panchadeepakini chooranam in management of Psoriasis(Kalanjagappadai)among patients attending special OPD at Government Siddha Medical College Hospital-A pilot study - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/073578

Enrollment

Registered

2024-09-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

Intervention1: Panchadeepakini Chooranam: 35 g of each raw drugs-Purified Zingiber officinale,Piper nigrum,Piper longum,Ellataria cardomom,Cuminum cyminum will be mildly roasted,powdered,sieved sepera

Eligibility

Inclusion criteria

Inclusion criteria: Patients with moderate and severe psoriasis characterized by PASI score greater than or equal to 5

Exclusion criteria

Exclusion criteria: Known case of Diabetes Mellitus Pregnant and lactating mothers

Design outcomes

Primary

Measure	Time frame
The rate of acheivement of PASI 50 or PASI 75 will be compared in both the study groupsTimepoint: 3 months	—

Secondary

Measure	Time frame
To estimate the reduction of investigatory parametersTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr G Ujjeevanam

Government Siddha Medical College, Chennai

ujjeevanam@gmail.com9884175653

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026